However, HGF derived from the tumor microenvironment has recently been shown to protect MET-amplified cells, otherwise sensitive to MET inhibitors, suggesting a role for the ligand in the resistance to anti-MET therapy, and providing the basis for the use of HGF-neutralizing drugs [106]. This evidence concerns the gene HGF and neoplasm.